Terms: = Head and neck cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346 AND Prognosis
19 results:
1. Long noncoding RNA MEG3 inhibits oral squamous cell carcinoma progression via gata3.
Hu Y; Lv F; Li N; Yuan X; Zhang L; Zhao S; Jin L; Qiu Y
FEBS Open Bio; 2023 Jan; 13(1):195-208. PubMed ID: 36468944
[TBL] [Abstract] [Full Text] [Related]
2. gata3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma.
Chi Z; Balani J; Gopal P; Hammer S; Xu J; Peng L
J Clin Pathol; 2023 Jul; 76(7):474-479. PubMed ID: 35039449
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological characteristics and outcomes of 23 patients with secretory carcinoma of major salivary glands.
Sun J; Liu S; Fu K; Gao N; Li R; He W; Gao Z
Sci Rep; 2021 Nov; 11(1):22639. PubMed ID: 34811395
[TBL] [Abstract] [Full Text] [Related]
4. [The role of brachytherapy in the curative treatment of oral cavity tumors].
Ferenczi Ö; Major T; Takácsi-Nagy Z
Orv Hetil; 2021 Sep; 162(37):1471-1479. PubMed ID: 34516393
[TBL] [Abstract] [Full Text] [Related]
5. [Secretory carcinoma of salivary gland: a clinicopathological and prognostic analysis of twelve cases].
Cao YS; Lyu XQ
Zhonghua Bing Li Xue Za Zhi; 2021 Aug; 50(8):899-903. PubMed ID: 34344073
[No Abstract] [Full Text] [Related]
6. Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population.
Luna-Ortiz K; Dominguez-Malagon H; Corredor-Alonso GE; Reynoso-Noveron N; Herrera-Ponzanelli C; Luna-Peteuil Z; Zacarias-Ramon LC
Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):327-333. PubMed ID: 33763743
[TBL] [Abstract] [Full Text] [Related]
7. Parathyroid carcinoma with sarcomatoid differentiation: a case report and literature review.
Hu L; Xie X
Diagn Pathol; 2020 Dec; 15(1):142. PubMed ID: 33317559
[TBL] [Abstract] [Full Text] [Related]
8. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract] [Full Text] [Related]
9. hdr interventional radiotherapy (brachytherapy) in the treatment of primary and recurrent head and neck malignancies.
Bussu F; Tagliaferri L; Mattiucci G; Parrilla C; Rizzo D; Gambacorta MA; Lancellotta V; Autorino R; Fonnesu C; Kihlgren C; Galli J; Paludetti G; Kovács G; Valentini V
Head Neck; 2019 Jun; 41(6):1667-1675. PubMed ID: 30701614
[TBL] [Abstract] [Full Text] [Related]
10. Stromal interleukin-33 promotes regulatory T cell-mediated immunosuppression in head and neck squamous cell carcinoma and correlates with poor prognosis.
Wen YH; Lin HQ; Li H; Zhao Y; Lui VWY; Chen L; Wu XM; Sun W; Wen WP
Cancer Immunol Immunother; 2019 Feb; 68(2):221-232. PubMed ID: 30357458
[TBL] [Abstract] [Full Text] [Related]
11. Mammary Analogue Secretory Carcinoma of the Thyroid Mimicking Locally Advanced Papillary Thyroid Carcinoma: A Rare Case Report.
Liao H; Khan A; Miron PM; Cornejo KM
Int J Surg Pathol; 2018 Aug; 26(5):459-463. PubMed ID: 29228842
[TBL] [Abstract] [Full Text] [Related]
12. Intensity modulated perioperative hdr brachytherapy for recurrent and/or advanced head and neck metastases.
Teudt IU; Kovàcs G; Ritter M; Melchert C; Soror T; Wollenberg B; Meyer JE
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2707-15. PubMed ID: 26498949
[TBL] [Abstract] [Full Text] [Related]
13. [The role of interstitial brachytherapy in multimodality management of solid tumors].
Soumarová R; Homola L; Perková H; Czudek S; Skrovina M; Adamcík L
Rozhl Chir; 2007 Oct; 86(10):533-9. PubMed ID: 18064791
[TBL] [Abstract] [Full Text] [Related]
14. Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.
Chiarion-Sileni V; Corti L; Ruol A; Innocente R; Boso C; Del Bianco P; Pigozzo J; Mazzarotto R; Tomassi O; Ancona E
Br J Cancer; 2007 Feb; 96(3):432-8. PubMed ID: 17245338
[TBL] [Abstract] [Full Text] [Related]
15. A comparison of brachytherapy and surgery for the treatment of stage I-II squamous cell carcinoma of the tongue.
Umeda M; Komatsubara H; Ojima Y; Minamikawa T; Shibuya Y; Yokoo S; Ishii J; Komori T
Int J Oral Maxillofac Surg; 2005 Oct; 34(7):739-44. PubMed ID: 15921890
[TBL] [Abstract] [Full Text] [Related]
16. [Carcinoma of the external ear canal and middle ear as interdisciplinary challenge for ear surgery and radiotherapy].
Schwager K; Pfreundner L; Hoppe F; Baier G; Willner J; Baier K
Laryngorhinootologie; 2001 Apr; 80(4):196-202. PubMed ID: 11383121
[TBL] [Abstract] [Full Text] [Related]
17. Salvage brachytherapy for patients with locally persistent nasopharyngeal carcinoma.
Leung TW; Tung SY; Sze WK; Sze WM; Wong VY; O SK
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):405-12. PubMed ID: 10802367
[TBL] [Abstract] [Full Text] [Related]
18. Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.
Uchino S; Noguchi S; Yamashita H; Sato M; Adachi M; Yamashita H; Watanabe S; Ohshima A; Mitsuyama S; Iwashita T; Takahashi M
Jpn J Cancer Res; 1999 Nov; 90(11):1231-7. PubMed ID: 10622534
[TBL] [Abstract] [Full Text] [Related]
19. Effect of multidisciplinary treatment with high dose rate intraluminal brachytherapy on survival in patients with unresectable esophageal cancer.
Iwasa M; Ohmori Y; Iwasa Y; Yamamoto A; Inoue A; Maeda H; Kume M; Ogoshi S; Nishioka A; Ogawa Y; Yoshida S
Dig Surg; 1998; 15(3):227-35. PubMed ID: 9845590
[TBL] [Abstract] [Full Text] [Related]
